Ceftaroline – «Sui Generis» | CMAC

Ceftaroline – «Sui Generis»

Clinical Microbiology and Antimicrobial Chemotherapy. 2013; 15(2):124-130

​ Kozlov R.S., Golub A.V.
ceftaroline cephalosporins communityacquired pneumonia skin and skin structure infections
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2013; 15(2):124-130

Abstract

Ceftaroline fosamil is a novel cephalosporin antibiotic that has a high activity against multiple bacterial pathogens, including important drug-resistant microorganisms. The main benefit of the ceftaroline fosamil compared to other beta-lactams is an activity against methicillin-resistant Staphylococcus aureus (MRSA). In addition, activity against Haemophilus influenzae (including beta-lactamase-producing strains), enteric bacteria, streptococci, and Streptococcus pneumoniae (including multidrugresistant strains) which is comparable to that of third- or fourth-generation cephalosporins makes ceftaroline suitable for the treatment of community-acquired pneumonia and skin and skin structure infections. This paper reviews characteristics of ceftaroline fosamil and clinical studies providing evidence of its efficacy in patients with the above infections.

  • 1. File T.M., Wilcox M.H., Stein G.E. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55 (Suppl. 3):173-80.
  • 2. Saravolatz L.D., Stein G.E., Johnson L.B. Ceftaroline: a novel cephalosporin with activity against methicillinresistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156-63.
  • 3. Brown S.D., Traczewski M.M. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271-4.
  • 4. Kosowski-Shick K., McGhee P., Appelbaum P. Affinity of ceftraoline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Strepotococcus pneumoniae. Antimicrob Agents Chemother 2010; 54:1670-7.
  • 5. McGee L., Biek D., Ge Y., et al. In vitro evaluation of antimicrobial activity of ceftaroline against cephalosporinresistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53:552-6.
  • 6. Fenoil A., Aguilar L., Robiedo O., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52:4209–10.
  • 7. Ge Y., Biek D., Talbot G. S. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:3398-407.
  • 8. Saravolatz L., Pawlak J., Johnson L. In vitro acitivity of ceftaroline against community-associated methicillinresistant, vancomycin-intermediate, vancomycin-resistant and daptomycin-nonsusceptilbe Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54:3027-30.
  • 9. Mushtaq S., Warner M., Ge Y., et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60:300-11.
  • 10. Citron D., Tyrrell K., Merriam C., et al. In vitro activity ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010; 54:1627-32.
  • 11. Farrell D.J., Flamm R.K., Jones R.N., et al. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn Mirobiol Infect Dis 2013; 75:86-8.
  • 12. Farrell D.J., Flamm R.K., Sander H.S., et al. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimicrob Agents 2013; 41:337-42.
  • 13. Riccobene T., Fang E., Thye D.A. A single- and multipledose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy - 46th Annual Meeting of the Infectious Diseases Society of America; 2008 Washington, DC. Abstract 1888.
  • 14. Ge J.Y., Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI0903M). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006 San Francisco, CA. Abstract 1935.
  • 15. Riccobene T., Jakate A., Rank D., et al. An open-label pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with endstage renal disease on intermittent haemodialysis. Clin Microbiol Infect 2009;15(Suppl. S4):S407.
  • 16. Белькова Ю.А. Пиодермии в амбулаторной практике. Клин микробиол антимикроб химиотер 2005; 7:255-70.
  • 17. Nikulin A., Dekhnich A., Ivanchik N., et al. Susceptibility of Staphylococcus aureus in the community settings in Russia. 19th ECCMID, Helsinki, Finland, 16-19 May 2009. Poster# P1077.
  • 18. Научный отчет о результатах исследования антибиотикорезистентности бактериальных возбудителей нозокомиальных инфекций в отделениях с интенсивным использованием антибиотиков в стационарах России (РеВАНШ). НИИ антимикробной химиотерапии. Смоленск, 2009.
  • 19. Corey G.R., Wilcox M.H., Talbot G.H., etal. CANVAS 1: The first phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patient with complicated skin and skin structured infections. J Antimicrob Chemother 2010; 65 (Suppl. 4):41-51.
  • 20. Wilcox M.H., Corey G.R., Talbot G.H., et al. CANVAS 2: The second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patient with complicated skin and skin structured infections. J Antimicrob Chemother 2010; 65 (Suppl. 4):53-65.
  • 21. Friedland H.D., O'Neal T., Biek D., et. al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structures infections. Antimicrob Agents Chemother 2012; 56:2231-6.
  • 22. Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей. Руководство для врачей. М.: Премьер МТ, Наш Город; 2007. – 352 с.
  • 23. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности S. pneumoniae к антибиотикам в России за период 1999-2009 гг. Клин микробиол антимикроб химиотер 2010; 12:329-41.
  • 24. File T.M., Low D.E., Eckburg P.B., et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 (Suppl. 3):19-32.
  • 25. Low D.E., File T.M., Eckburg P.B., et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.J Antimicrob Chemother 2011;66 (Suppl. 3):33-44.
  • 26. File T.M., Low D.E., Eckburg P.B., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubledblinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-405.
  • 27. Eckburg P.B., Friedland H.D., Llorens L., et. al. Day 4 clinical response of ceftaroline fosamile versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis ClinPract 2012; 20:254-60.
  • 28. Shorr A.F., Kollef M., Eckburg P.B., et al. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterialpneumonia due to Streptococcus pneumoniae: insights from two randomizedtrials. Diagn Mirobiol Infect Dis 2013; 75:298-303.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared